Belimumab for the management of systemic lupus erythematosus.

about

Neuropsychiatric Symptoms in Lupus Belimumab in the management of systemic lupus erythematosus - an update.VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus

P2860

Q34459628-07AE89F3-CFFD-4A9F-B3D4-8F7234A906FD Q38810737-23B2FC05-B161-451F-92E8-2F6241192F1D Q57081512-3FBC3B58-FDB8-468E-B632-56E49D641161

P2860

Belimumab for the management of systemic lupus erythematosus.

Item

http://www.wikidata.org/entity/Q38014539

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Belimumab for the management of systemic lupus erythematosus.

@en

type

Item

label

Belimumab for the management of systemic lupus erythematosus.

@en

prefLabel

Belimumab for the management of systemic lupus erythematosus.

@en

P1476

Belimumab for the management of systemic lupus erythematosus.

@en

P2093

David P D'Cruz

http://www.w3.org/2001/XMLSchema#string

Pamela M K Lutalo

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data.

Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Reproductive and menopausal factors and risk of systemic lupus erythematosus in women.

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

Novel evidence-based systemic lupus erythematosus responder index.

P304

957-963

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2012.682980

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22646798

http://www.w3.org/2001/XMLSchema#string

Belimumab for the management of systemic lupus erythematosus.

about

P2860

P2860

Belimumab for the management of systemic lupus erythematosus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698